论文部分内容阅读
目的了解肺癌患者外周血中CD4+CD25+调节性T淋巴细胞的比例和其临床意义,探讨CD4+CD25+调节性T细胞与临床分期的相关性。方法流式细胞分析仪检测外周血中CD4+CD25+调节性T细胞占CD4+T细胞的比例。结果肺癌患者外周血中CD4+CD25+调节性T细胞占CD4+T淋巴细胞的百分比为(15.7±1.6)%,明显高于健康对照者(7.1±1.5)(p<0.05),且外周血中CD4+CD25+调节性T细胞水平与患者病情分期呈显著正相关。结论肺癌患者外周血中具有免疫抑制活性的CD4+CD25+调节性T细胞比例较高,对肺癌患者具有免疫抑制功能。
Objective To investigate the proportion of CD4 + CD25 + regulatory T lymphocytes in peripheral blood of patients with lung cancer and its clinical significance and to explore the correlation between CD4 + CD25 + regulatory T cells and clinical stage. Methods The ratio of CD4 + CD25 + regulatory T cells to CD4 + T cells in peripheral blood was detected by flow cytometry. Results The percentage of CD4 + CD25 + regulatory T cells in CD4 + T lymphocytes in peripheral blood of patients with lung cancer was (15.7 ± 1.6)%, significantly higher than that of healthy controls (7.1 ± 1.5) (p <0.05) The level of CD4 + CD25 + regulatory T cells was positively correlated with the stage of patients’ disease. Conclusion The proportion of CD4 + CD25 + regulatory T cells with immunosuppressive activity in peripheral blood of patients with lung cancer is high, and they have immunosuppressive function in patients with lung cancer.